Mandatory notification regarding exercise and trade of subscription rights and trade of shares

Posted on Dec 21, 2016

Oslo, December 21, 2016 – Overview of mandatory notification regarding exercise and trade of subscription rights and trade of shares. Management and the board of directors of PCI Biotech Holding ASA (“PCI Biotech” or “the Company”) are all supportive to the share issue resolved by the extra ordinary general meeting 8 December 2016. In total the transactions disclosed herein leads to a net increase in shareholding by primary insiders of PCI Biotech of 91.549 shares and in addition other employees have a net increase in shareholdings of 10.856 shares. The following transactions are made: 

1. Exercise of subscription rights and sale of shares today, 21 December 2016 

This section details the exercise of subscription rights and, where relevant, sale of shares done to finance all or parts of the subscription rights exercised. 

Per Walday, CEO, has subscribed for 29.542 new shares in the Company at a subscription price of NOK 7 per share by exercising 29.542 subscription rights in the Company’s ongoing rights issue and has simultaneously sold a total of 10.000 shares at an average price of NOK 12.15 per share. After the transactions, Per Walday will have a total shareholding in the Company of 63.561 shares, 0 subscription rights in the rights issue and 25.000 unexercised stock options in relation to the Company’s stock option scheme. For a total overview of holdings, see section 4. 

Ronny Skuggedal, CFO, has subscribed for 10.066 new shares in the Company at a subscription price of NOK 7 per share by exercising 10.066 subscription rights in the Company’s ongoing rights issue. After the transaction, Ronny Skuggedal will have a total shareholding in the Company of 25.066 shares, 0 subscription rights in the rights issue and 66.000 unexercised stock options in relation to the Company’s stock option scheme. For a total overview of holdings, see section 4. 

Anders Høgset, CSO, has subscribed for 32.198 new shares in the Company at a subscription price of NOK 7 per share by exercising 32.198 subscription rights in the Company’s ongoing rights issue and has simultaneously sold a total of 18.800 shares at an average price of NOK 12.15 per share. After the transactions, Anders Høgset will have a total shareholding in the Company of 61.375 shares, 0 subscription rights in the rights issue and 17.000 unexercised stock options in relation to the Company’s stock option scheme. For a total overview of holdings, see section 4. 

Kristin Eivindvik, PD, has subscribed for 8.882 new shares in the Company at a subscription price of NOK 7 per share by exercising 8.882 subscription rights in the Company’s ongoing rights issue and has simultaneously sold a total of 5.250 shares at an average price of NOK 12.15 per share. After the transactions, Kristin Eivindvik will have a total shareholding in the Company of 16.867 shares, 0 subscription rights in the rights issue and 24.500 unexercised stock options in relation to the Company’s stock option scheme. For a total overview of holdings, see section 4. 

The Board of Director’s member, Christina Herder, has subscribed for 3.355 new shares in the Company at a subscription price of NOK 7 per share by exercising 3.355 subscription rights in the Company’s ongoing rights issue. After the transaction, Christina Herder will hold a total shareholding in the Company of 8.355 shares and 0 subscription rights in the rights issue. For a total overview of holdings, see section 4. 

In addition, the Chairman Hans Peter Bøhn subscribed for 33.556 new shares in the Company’s ongoing rights issue at 14 December 2016 (the transaction was also disclosed 14 December 2016). After the transaction, Hans Peter Bøhn will have a total shareholding in the company of 83.556 shares and 0 subscription rights in the rights issue. Hans Peter Bøhn has previously entered into a guarantee agreement of NOK 1 000 000 in relation to the rights issue, and the exercise of subscription rights will, in compliance with the guarantee agreement, reduce the guarantee liability correspondingly. For a total overview of holdings, see section 4. 

2. Sale of subscription rights today, 21 December 2016 

Gaël L’Hévéder, CBDO, has sold 6.711 subscription rights at an average price of NOK 5.05 per subscription right. After the transaction, Gaël L’Hévéder holds 10.000 shares, 0 subscription rights in the rights issue and 91.000 unexercised stock options in relation to the Company’s Stock option scheme. For a total overview of holdings, see section 4. 

3. Purchase of shares today, 21 December 2016 

The board of Director’s member Lars Viksmoen has purchased 4.000 shares in the Company at an average share price of NOK 12.15 per share. The transaction is made through his fully owned company, Stocken Invest AS, and the purchase is made from other primary insiders in the Company. After the transaction, Lars Viksmoen, holds a total of 4.000 shares in the Company. For a total overview of holdings, see section 4. 

The board of Director’s member Kjetil Taskén has purchased 4.000 shares in the Company at an average share price of NOK 12.15 per share. The transaction is made through his fully owned company, Kjetil Tasken AS, and the purchase is made from other primary insiders in the Company. After the transaction, Kjetil Tasken, holds a total of 4.000 shares in the Company. For a total overview of holdings, see section 4. 

In addition, one employee has purchased 4.000 shares from primary insiders in the Company at an average share price of NOK 12.15 per share.  

4. Overview new holdings per 21 December 2016 

For a complete overview of new holdings after the transactions disclosed above and completion of the rights issue, please see attachment. In total the transactions disclosed herein leads to a net increase in shareholding by primary insiders of PCI Biotech of 91.549 shares and in addition other employees have a net increase in shareholdings of 10.856 shares. 

Attachment section 4 Overview new holdings

For further information, please contact

Ronny Skuggedal, CFO          
rs@pcibiotech.no
Mobile: +47 9400 5757